Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Mitapivat (AG-348) in Not Regularly Transfused Adults With Pyruvate Kinase Deficiency
2017-003823-31Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pyruvate kinase deficiency (PKD) comparing Mitapivat with Placebo (2 arms). Primary endpoint: Hemoglobin response. Started Apr 2018; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on 2017-003823-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003823-31.